Trans ε viniferin decreases amyloid deposits and inflammation in a mouse transgenic Alzheimer model

Martial Caillaud (1) , Jérôme Guillard (2) , Damien Richard (3) , Serge Milin (1, 4) , Damien Chassaing (1) , Marc Paccalin (1, 4) , Guylène Page (1) , Agnès Rioux Bilan (1)

1 Neuvacod - Unité neurovasculaire et troubles cognitifs
2 IC2MP [Poitiers] - Institut de chimie des milieux et matériaux de Poitiers [UMR 7285]
3 Neuro-Dol - Neuro-Dol
4 CHU de Poitiers - Centre hospitalier universitaire de Poitiers = Poitiers University Hospital

As Alzheimer's disease (AD) induces several cellular and molecular damages, it could be interesting to use multi-target molecules for therapeutics. We previously published that trans ε-viniferin induced the disaggregation of Aβ42 peptide and inhibited the inflammatory response in primary cellular model of AD. Here, effects of this stilbenoid were evaluated in transgenic APPswePS1dE9 mice. We report that trans ε-viniferin could go through the blood brain barrier, reduces size and density of amyloid deposits and decreases reactivity of astrocytes and microglia, after a weekly intraperitoneal injection at 10 mg/kg from 3 to 6 months of age.

Domaines: Médecine humaine et pathologie

Martial Caillaud, Jérôme Guillard, Damien Richard, Serge Milin, Damien Chassaing, et al.. Trans ε viniferin decreases amyloid deposits and inflammation in a mouse transgenic Alzheimer model. PLoS ONE, 2019, 14 (2), pp.e0212663. ⟨10.1371/journal.pone.0212663⟩. ⟨hal-03279054⟩